Managing the care of multiple myeloma has become more challenging with the recent advances in risk stratification and the complexities that are further defined with next generation sequencing and genomic characterization of patients with multiple myeloma. As treatment improves and we have more FDA approved agents for myeloma, we begin to ask how and when to treat patients with all of these novel options of therapy available for our patients and how to assess their response, especially the use of MRD testing. In this session, we provide discussion on these hot topics in myeloma and the challenges facing us in managing patients with myeloma.
Dr. Kaufman will summarize recent advances in risk stratification of patients with myeloma. He will describe current definitions of high risk myeloma and how this is changing in the era of next generation sequencing and how to adapt our therapy for patients with high risk myeloma
Dr. Lentzcsh will then discuss the challenges facing clinicians in treating relapsed and refractory myeloma patients who are not eligible for clinical trials. She will describe recent FDA approvals for agents in the refractory setting and how to adapt therapy for refractory myeloma.
Dr. Manasanch will clarify challenges in the use of minimal residual disease (MRD) testing in patients with myeloma. She will describe the utility of MRD testing and when to use it in current clinical practice. She will also describe current clinical trials using MRD as endpoints for altering therapy in myeloma.